Costas Christos Loullis

US Patent:

6346283, Feb 12, 2002

Filed:

Dec 30, 1999

Appl. No.:

09/475494

Inventors:

Keith Hoffman - Del Mar CA
Costas Loullis - Carlsbad CA

Assignee:

Ancile Pharmaceuticals

International Classification:

A61K 3578

US Classification:

424733, 514183, 514906

Abstract:

A novel method of inhibiting at least one symptomology of Restless Legs Syndrome (RLS) and its related disorders, including disorders such as periodic limb movements in sleep (PLMS) and periodic limb movement disorder (PLMD), is disclosed. Said method optionally comprising identifying a host, preferably a human, afflicted with Restless Legs Syndrome (RLS) and its related disorders; and comprising administering to said host a pharmaceutically effective amount of Valeriana, preferably an extract of Valeriana. A novel method of inhibiting at least one symptomology of Restless Legs Syndrome (RLS) and its related disorders is disclosed. The method may also be used to treat a host in order to diminish undesired limb movements, and may involve the administration of a particular compound, found in the above-mentioned extracts, preferably selected from the group consisting of 10(14)-Aromadendren-4-ol, 6,10(14)-Guaiadien-4-ol, Valerenal, Valerenol, Valerenic acid, Acetoxyvalerenic acid, Hydroxyvalerenic acid, mimetics thereof, and may involve the administration of a combinations of these particular compounds and mimetics thereof.

US Patent:

6544565, Apr 8, 2003

Filed:

Nov 28, 2001

Appl. No.:

09/995538

Inventors:

Keith Hoffman - Del Mar CA
Costas Loullis - Carlsbad CA

Assignee:

Ancile Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 3578

US Classification:

424733, 514183, 514906, 514724, 514729

Abstract:

A method of inhibiting at least one symptomology of Restless Leg Syndrome (RLS) and its related disorders, including disorders such as periodic limb movements in sleep (PLMS) and periodic limb movement disorder (PLMD), is disclosed. The method optionally comprising identifying a host, afflicted with Restless Leg Syndrome (RLS) and its related disorders; and administering to the host a pharmaceutically effective amount of Valeriana. A novel method of inhibiting at least one symptomology of Restless Leg Syndrome (RLS) and its related disorders is disclosed. The method may also be used to treat a host in order to diminish undesired limb movements, and may involve the administration of a particular compound, found in the above-mentioned extracts, preferably selected from the group consisting of 10(14)-Aromadendren-4-ol, 6,10(14)-Guaiadien-4-ol, Valerenal, Valerenol, Valerenic acid, Acetoxyvalerenic acid, Hydroxyvalerenic acid, mimetics thereof, and may involve the administration of a combinations of these particular compounds and mimetics thereof.

US Patent:

57600015, Jun 2, 1998

Filed:

May 22, 1995

Appl. No.:

8/447143

Inventors:

Beverly E. Girten - San Diego CA
Richard A. Houghten - Del Mar CA
Costas C. Loullis - Cardiff CA
Mark J. Suto - San Deigo CA
Ronald R. Tuttle - Escondido CA

Assignee:

Trega Biosciences, Inc. - San Diego CA

International Classification:

A61K 3800

US Classification:

514 16

Abstract:

The present invention relates to novel peptides that are potent cytokine restraining agents. In addition, the present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a cytokine restraining agent. Administration of such a cytokine restraining agent to a subject restrains, but does not necessarily suppress, cytokine activity completely. Thus, the present invention provides a method of restraining pathologically elevated cytokine activity in a subject. The invention also provides methods of treating disuse deconditioning and diseases mediated by nitric oxide and cytokines, such as diabetes and glomerulonephritis, a method of organ protection, a method of organ protection, and a method of reducing the negative side effects of cancer chemotherapy, such as nephrotoxicity.

US Patent:

57261563, Mar 10, 1998

Filed:

Sep 12, 1995

Appl. No.:

8/527056

Inventors:

Beverly E. Girten - San Diego CA
Ali Andalibi - San Diego CA
Amaresh Basu - San Diego CA
Patrick Fagan - Escondido CA
Richard A. Houghten - Del Mar CA
Costas C. Loullis - Cardiff CA
Paul Omholt - San Diego CA
Ronald R. Tuttle - Escondido CA
Mark J. Suto - San Diego CA
Patricia A. Weber - Stevensville MT

Assignee:

Trega Biosciences, Inc. - San Diego CA

International Classification:

A61K 3800

US Classification:

514 16

Abstract:

The present invention relates to novel peptides that are potent cytokine regulatory agents. In addition, the present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a cytokine regulatory agent. Administration of such a cytokine regulatory agent to a subject can enhance or restrain cytokine activity. Thus, the present invention provides a method of regulating cytokine activity in a subject having a condition characterized by aberrant or altered cytokine activity. The invention also provides methods of treating such conditions, including, for example, disuse deconditioning, diseases mediated by nitric oxide and cytokines, adverse drug reactions, obesity, septic shock, and adverse side effects due to cancer chemotherapy or occurring as in response to organ transplantation.

US Patent:

62457381, Jun 12, 2001

Filed:

Nov 9, 1994

Appl. No.:

8/336473

Inventors:

Mark J. Suto - San Diego CA
Beverly E. Girten - San Diego CA
Richard A. Houghten - Solana Beach CA
Costas C. Loullis - Cardiff CA
Ronald R. Tuttle - Escondido CA

Assignee:

Trega Biosciences, Inc. - San Diego CA

International Classification:

A61K 3800

US Classification:

514 8

Abstract:

The present invention provides novel cytokine restraining agents, which limit or control the biological activity of cytokines. The invention also provides pharmaceutical compositions comprising a cytokine restraining peptide and methods of administering the pharmaceutical composition to a subject. The invention further provides methods for using the novel peptides to restrain cytokine activity in a subject.

US Patent:

57863326, Jul 28, 1998

Filed:

Mar 6, 1995

Appl. No.:

8/400983

Inventors:

Beverly E. Girten - San Diego CA
Richard A. Houghten - Del Mar CA
Costas C. Loullis - Cardiff CA
Mark J. Suto - San Diego CA
Ronald R. Tuttle - Escondido CA

Assignee:

Trega Biosciences, Inc. - San Diego CA

International Classification:

A61K 3800

US Classification:

514 16

Abstract:

The present invention relates to novel peptides that are potent cytokine restraining agents. In addition, the present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a cytokine restraining agent. Administration of such a cytokine restraining agent to a subject restrains, but does not necessarily suppress, cytokine activity completely. Thus, the present invention provides a method of restraining pathologically elevated cytokine activity in a subject. The invention also provides methods of treating disuse deconditioning and diseases mediated by nitric oxide and cytokines, such as diabetes and glomerulonephritis, a method of organ protection, a method of organ protection, and a method of reducing the negative side effects of cancer chemotherapy, such as nephrotoxicity.

US Patent:

54201098, May 30, 1995

Filed:

Nov 12, 1993

Appl. No.:

8/151534

Inventors:

Mark J. Suto - San Diego CA
Beverly E. Girten - San Diego CA
Richard A. Houghten - Solana Beach CA
Costas C. Loullis - Cardiff CA
Ronald R. Tuttle - Escondido CA

Assignee:

Houghten Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 3800
C07K 500
C07K 700
C07K 1700

US Classification:

514 8

Abstract:

The present invention provides novel cytokine restraining agents, which limit or control the biological activity of cytokines. The invention also provides pharmaceutical compositions comprising a cytokine restraining peptide and methods of administering the pharmaceutical composition to a subject. The invention further provides methods for using the novel peptides to restrain cytokine activity in a subject.